DEA Targets Synthetic Kratom Derivatives Amid Growing Safety Concerns
New federal regulations aim to curb synthetic kratom while advocates seek clearer industry standards.
1Federal Regulatory Shift
The Drug Enforcement Administration is revising its scheduling criteria for kratom-based products. This initiative specifically targets synthetic derivatives rather than the natural Mitragyna speciosa plant. The move follows advice from the Department of Health and Human Services, aiming to address public health risks associated with highly concentrated, unregulated synthetic compounds currently circulating.
2Synthetic vs Natural Risks
Synthetic kratom products often contain elevated concentrations of 7-hydroxymitragynine, significantly increasing potency. These products are frequently sold over-the-counter without clear labeling, leading to accidental misuse. Unlike natural kratom, these synthetic variants have been linked to fatal overdoses, including recent incidents in Los Angeles and at the University of Mississippi.
3Advocacy Group Alignment
The American Kratom Association, previously a staunch opponent of federal scheduling, now supports the DEA's targeted approach. Mac Harrow, a senior fellow at the organization, confirmed their support for banning synthetic derivatives. Advocates view this as a potential middle ground to protect consumers while maintaining access to natural leaf-based kratom products.
4Prevalence of Kratom Use
Data indicates that approximately 1.7 million Americans aged 12 and older used kratom in 2021. A University of Michigan study suggests that lifetime usage may reach five million people, including over 100,000 adolescents. This widespread adoption has fueled intense debates regarding its safety, efficacy, and potential for treating substance use disorders.
5Therapeutic Claims Debated
Proponents argue that natural kratom serves as a safer alternative for managing chronic pain or weaning off opioids. However, researchers like Sean McCabe emphasize that the FDA has not approved kratom for any medical condition. Critics maintain that there are already proven, tested medications available for addiction treatment that carry fewer unknown risks.
6Specific Regulatory Thresholds
The DEA's proposed regulations focus on specific thresholds for 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16. By setting these limits, the agency intends to differentiate between natural products and enhanced synthetics. While the AKA previously sued over these definitions, they now believe the current framework sufficiently isolates dangerous synthetic products from the market.
7Legislative Gaps Remain
Advocates argue that current DEA authority is limited to identifying existing market products. They are pushing for Congress to enact the Kratom Consumer Protection Act, which would mandate third-party testing and age limits. This federal standard would replace the current patchwork of state regulations, providing a more consistent safety net for consumers.
8Systemic Treatment Shortfalls
Experts suggest that the kratom crisis highlights deeper issues in the U.S. addiction treatment landscape. There is a documented lack of funding and trained professionals, such as addiction psychiatrists, to meet current demand. This resource gap drives individuals toward unregulated alternatives, creating a cycle of dependency that is difficult to break.
9Future Industry Outlook
The DEA's temporary scheduling is expected to take effect next month, though long-term policy remains fluid. Moving forward, a potential compromise involves taxing low-addiction natural kratom to fund evidence-based care. Ultimately, the industry faces pressure to adopt uniform standards to prevent an arms race of increasingly potent and dangerous synthetic products.
Original article: Gizmodo — DEA Targets Synthetic Kratom Derivatives Amid Growing Safety Concerns